- Approval Id
- bf47b0b9d401a618
- Drug Name
- LYSAKARE SOLUTION FOR INFUSION 25G / 25G
- Product Name
- LYSAKARE SOLUTION FOR INFUSION 25G / 25G
- Approval Number
- SIN16003P
- Approval Date
- 2020-08-31
- Registrant
- NOVARTIS (SINGAPORE) PTE LTD
- Licence Holder
- NOVARTIS (SINGAPORE) PTE LTD
- Drug Type
- Therapeutic
- Forensic Classification
- Prescription Only
- Dosage Form
- INFUSION, SOLUTION
- Dosage
- **4 Dosage regimen and administration**
Since LysaKare is indicated for administration during PRRT with lutetium (177Lu) oxodotreotide, it should only be administered by a healthcare provider experienced in the use of PRRT.
Please refer to full prescribing information of lutetium (177Lu) oxodotreotide.
**Dosage regimen**
**General target population**
**Adults**
The recommended treatment regimen in adults consists of infusion of a full bag of LysaKare concomitantly with lutetium (177Lu) oxodotreotide. The dose of LysaKare should not be decreased even if the dose of lutetium (177Lu) oxodotreotide is reduced.
Pre-treatment with an antiemetic is recommended to prevent nausea and vomiting. Antiemetics should be administered with sufficient lead time prior to the start of LysaKare. Please refer to the full prescribing information of the antiemetic for administration instructions.
**Special populations**
**Renal impairment**
Due to the potential for clinical complications related to volume overload and an increase of potassium in blood associated with the use of LysaKare, this product should not be administered in patients with creatinine clearance <30 mL/min. Care should be taken with LysaKare use in patients with creatinine clearance between 30 and 50 mL/min, due to a potential increased risk of transient hyperkalemia in these patients (see section Warnings and precautions – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_).
**Hepatic impairment**
The use of arginine and lysine has not been specifically studied in patients with hepatic impairment (see section Warnings and precautions – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_).
**Pediatric patients (below 18 years)**
The safety and efficacy of LysaKare in pediatric patients (below 18 years) has not been established. No data are available.
**Geriatric patients (65 years or above)**
No studies have been performed in patients 65 years of age or above.
Because elderly patients are more likely to have decreased renal function, care should be taken in determining eligibility based on creatinine clearance (see section Warnings and precautions – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_).
**Method of administration**
For intravenous (IV) use only.
LysaKare should be administered as a 4-hour IV infusion (250 mL/hour). The infusion must be initiated 30 minutes prior to administration of lutetium (177Lu) oxodotreotide to achieve optimal renal protection.
LysaKare and lutetium (177Lu) oxodotreotide must be administered through separate infusion lines.
- Route Of Administration
- INTRAVENOUS
- Indication Info
- **3 Indications**
LysaKare is indicated for reduction of renal radiation exposure during peptide-receptor radionuclide therapy (PRRT) with lutetium (177Lu) oxodotreotide in adults.
- Contraindications
- **5 Contraindications**
None.
- Atc Code
- V03AF11
- Atc Item Name
- arginine and lysine
- Pharma Manufacturer Name
- NOVARTIS (SINGAPORE) PTE LTD
- Company Detail Path
- /organization/novartis-singapore-pte-ltd
